Strategic Advice. Proven Execution. Deep Sector Expertise.

Rahul Chaudhary is senior managing director, head of equity capital markets (ECM) at Leerink Partners, where he has successfully led his team for more than a decade. In addition to overseeing the group, he is responsible for the origination and execution of all varieties of public and private equity offerings, including IPOs, follow-ons and private investments in public equity. Since joining the company in 2009, Rahul has led more than 500 book run offerings, including more than 150 IPOs.

Formerly, he served as an integral part of Merrill Lynch’s ECM group, where he focused on origination and execution of healthcare equity and equity-linked transactions. Rahul began his career at Merrill Lynch in 2004 in the investment banking group, centered on the consumer sector, where he worked on a variety of equity, debt and M&A assignments.

Rahul earned a bachelor’s degree in finance from the University of Illinois.

Jack Bannister is a Senior Managing Director on the Equity Capital Markets team at Leerink Partners. He partners with healthcare and life sciences companies to raise capital and position them for success in the public markets.

Jack joined the Firm in 2021 from Goldman Sachs where he served as Vice President of the Healthcare Equity Capital Markets team. He began his career as an Equity Analyst with T. Rowe Price in Baltimore.

He holds a Bachelor of Arts from the University of North Carolina at Chapel Hill and an MBA from the University of Virginia Darden School of Business.

Prasanth “Burri” Rao-Kathi is a Senior Managing Director at Leerink Partners and leads the Firm’s Convertibles business.

Prior to joining the Firm in 2016, he was the Head of Equity-Linked (Convertibles) Origination in the Equity Capital Markets group at Bank of America Merrill Lynch. Burri joined the ECM group at Merrill Lynch in 1999 and worked on a number of Merrill Lynch’s landmark convertible innovations over the last 15 years including: Contingent Conversion, Contingent Payment, Bond Hedges, HiPrs, Collateralization, Simultaneous Bond and Stock Repurchases, and Prepaid Forwards in conjunction with new issues. Prior to joining Merrill Lynch, he worked in Fixed Income Swaps Marketing and Trading and Corporate Finance/ Mergers and Acquisitions at J.P. Morgan.

He is a Magna Cum Laude graduate of Georgetown University with double majors in Finance and International Business and a minor in English. He received his M.B.A. in Finance from the Wharton School of Business at the University of Pennsylvania.

Seth M. Christian is a Senior Managing Director at Leerink Partners, leading trading for our Alternative Equities business. He has over 20 years of buy-side experience and has leveraged his healthcare fund expertise to maximize trading opportunities for one of the top franchises in At-The-Market (ATM) offerings.

Prior to joining the Firm, Seth was a Managing Director and Head of Trading and Capital Markets at Broadfin Capital. He had a similar role and was on the launch team at the healthcare-focused fund, March Altus Capital. Earlier in his career, Seth held trading roles at Angel Lane Principal Strategy, Catapult/Millenium Partners and Sapphire Capital.

He earned a B.A. in Economics from Tufts University.

Peter M. Fry is a Senior Managing Director at Leerink Partners leading our Alternative Equities business. He has over 25 years of experience on both sell-side & buy-side and has built one of the market-leading franchises in At-The-Market (ATM) offerings.

Prior to joining the Firm, Peter was a Managing Director and Head of Alternative Equities at H.C. Wainwright & Co. He held similar leadership roles at Guggenheim Securities and Burrill & Company. Earlier in his career, he spent eight years as Senior Investment Officer at Kingsbridge Capital and was a Senior Healthcare Banker and Head of Public/Private Placements at Investec Inc. and RBC Capital Markets.

He earned a B.A. in Economics and Finance from Bucknell University.

Richard Mei is a Senior Managing Director at Leerink Partners focused on Equity-Linked Capital Markets.

Prior to joining the Firm in 2018, Richard was a member of the corporate finance team at Regeneron Pharmaceuticals. He has over 16 years of experience advising companies on convertible financing, equity derivatives, and liability management. Prior to Regeneron, he spent over a decade at Bank of America Merrill Lynch in various investment banking and capital markets roles.

He earned an M.B.A. from New York University and a B.S. from the University of California at Berkeley.

Patrick Morley is a Senior Managing Director in Leerink Partners’ Equity Capital Markets group, advising private and public healthcare companies on the optimal strategy and tactics to achieve their financing goals. He joined the Firm in 2011 as a member of the Healthcare Investment Banking group before transitioning to his current role.

He earned bachelor’s degrees in Industrial Engineering and Finance from Lehigh University, and is a CFA charterholder.

Dan Dubin, M.D., is the Vice Chairman, Co-President, Global Co-Head of Investment Banking at Leerink Partners and sits on the Firm’s executive committee.

For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients.  In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Tom Davidson is Vice Chairman, Co- President, and Global Co-Head of Investment Banking.  He serves on the Firm’s executive committee, where he shares responsibility for shaping the long-term strategy and driving the growth of Leerink Partners. Drawing on over three decades of experience advising CEOs and boards in the biopharma sector, Tom is focused on building a world class Mergers & Acquisitions business at Leerink Partners.

Over the last decade, Tom has been one of the most active M&A advisors in the biopharma sector globally. Notable recent deals include Amgen’s $27.3 billion acquisition of Horizon Therapeutics, the largest life sciences transaction of 2022, CSL’s $11.7 billion acquisition of Vifor, the largest life sciences transaction of 2021 and the $50 billion combination of Mylan and Upjohn which closed in 2020. In addition to his recurring work with some of the largest companies in the sector, he focuses a majority of his practice on working with emerging growth biotechnology companies, including Crown Laboratories, Novavax and Protagonist Therapeutics, each during 2024.

Tom joined the Firm in 2024 from PJT Partners where he was a founding partner of the firm. He previously served as Vice Chairman and Global Co-Head of Healthcare Investment Banking at Credit Suisse, where he was a member of the Global Investment Banking Operating Committee and as a Managing Director at Merrill Lynch.

Tom graduated from Yale University, summa cum laude and Phi Beta Kappa, with a BA in Economics and received his MBA from the Wharton School of the University of Pennsylvania.  Tom is a member of the Board of Trustees of the Rye Country Day School in Rye, NY.     

Dan Lepanto is a Senior Managing Director at Leerink Partners and leads the Biopharma Mergers & Acquisitions team.

Prior to joining the firm in 2008, Dan spent 10 years at Cowen and Company where he executed a range of biopharma M&A transactions. Dan began his career in the Mergers & Acquisitions group at Wasserstein Perella. He has advised on a number of biopharma and health care transactions over the span of his career including the sale of Dicerna to Novo Nordisk, the sale of Dermira to Eli Lilly, the sale of NPS to Shire, the sale of Cynosure to Hologic, the sale of TKT to Shire, the sale of GelTex to Genzyme, the merger of Total Renal Care with Renal Treatment Centers and the acquisition of Vivra by Gambro.

He earned his B.S. in Finance with High Honors from Pennsylvania State University.

Philip Boyd is a Senior Managing Director in Investment Banking at Leerink Partners, he will help lead M&A efforts across Healthcare Services and Technology as well as support clients in the Healthcare Services Providers space. Phil has advised a wide variety of clients on mergers and acquisitions, divestitures, spin-offs, recapitalizations, leveraged buyouts, takeover defense, and capital raising.

Phil joined the Firm in 2024 from Guggenheim Securities, where he spent nearly a decade in the healthcare services sector, leading efforts to execute strategic transactions involving both public and private companies. Earlier in his career, he was an associate in Citigroup’s Healthcare Investment Banking Group.

He earned his B.S. in Applied Economics and Management and his M.B.A. from Cornell University.

Ben Brown is a Senior Managing Director in Investment Banking at Leerink Partners and leads the Firm’s Pharma Services practice. With over 20 years of Investment Banking and investing experience, he has executed M&A and equity transactions for clients across several verticals, including pharma outsourcing and IT, payor and provider services, healthtech, software, consulting and human capital services.

Ben joined Leerink Partners in 2021 from Baird, where he spent over 15 years, most recently as Managing Director and Head of Global Pharma Services Investment Banking. Prior to Baird, he held Investment Banking and private equity positions with Thomas Weisel Partners, The Halifax Group, Growth Capital Partners and Prudential Capital Group.

He holds a B.B.A. from Southern Methodist University (cum laude) and an M.B.A. from Northwestern University, Kellogg School of Management.

Gabe Cavazos is a Senior Managing Director in Investment Banking at Leerink Partners.

Gabe joined Leerink Partners in 2008 from J.P. Morgan where he was a member of the Mergers & Acquisitions group in the New York office. He covers East Coast and European biopharma companies and has 15+ years of transaction experience, including more than 100 transactions across M&A advisory, equity and equity linked financings. Prior to J.P. Morgan, he spent eight years in the pharmaceutical industry at Merck and Pfizer.

He earned his M.B.A. from the Kellogg School of Management at Northwestern University and a B.S. from The University of Michigan.

Jon Civitarese is a Senior Managing Director in Investment Banking at Leerink Partners.

Jon was one of the Firm’s earliest employees when he joined in 1995, providing advisory services to high-net-worth individuals in the Private Client Group prior to moving to Investment Banking. Since 1999, his activities have included advising public and private life science companies on strategic initiatives and equity capital financings as part of the Firm’s investment banking team. In addition to his primary banking responsibilities, he has also served as a senior member of the equity capital markets and syndicate team since 2001.

He began his career by serving in the U.S. Army as an infantry soldier, and later graduated from the University of Maine.

Michael Clifford is a Senior Managing Director in Investment Banking at Leerink Partners covering Healthcare Technology and Services and supporting the Firm’s Mergers & Acquisitions efforts.

With more than 13 years of Healthcare Investment Banking experience, he has led efforts to execute strategic transactions for a variety of public and private companies on mergers & acquisitions, equity offerings (IPOs, follow-ons and private placements), acquisition financings and debt financings. Michael joined the Firm in 2015 from Wells Fargo Securities where he worked in the Consumer and Healthcare Investment Banking Group covering Healthcare Technology and Services verticals. Prior to Wells Fargo Securities, he worked in the Transaction Services group at PwC in New York.

He holds a BSBA (cum laude) in Financial Management & Investments and Accounting from the University of Arkansas.

Grant Curry is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2024, Grant was most recently a Managing Director at Dyalco, specializing in mergers & acquisitions and activism defense. He has advised on a wide range of biopharma and health care transactions, including Bristol-Myers Squibb in its acquisition of Celgene, Bristol-Myers Squibb in its acquisition of MyoKardia, Novartis on its spin-off of Sandoz, Novartis in its acquisition of AveXis, Novartis in the divestment of its consumer healthcare joint venture interest to GSK, Amgen in its acquisition of Otezla, and Charles River Laboratories in its acquisition of Cognate. Prior to joining Dyalco in 2016 as one of its first employees, Grant was a member of the Global Healthcare Group of UBS.

He earned an M.B.A. from The University of Chicago Booth School of Business and a B.A. from Whitman College.

Howard Dingle is a Senior Managing Director in Investment Banking at Leerink Partners and is focused on coverage of Healthcare Distribution, Technology and related Services companies. With 12+ years of Healthcare Investment Banking experience, he has worked extensively with both private and publicly listed firms on mergers & acquisitions, equity offerings, acquisition financings and debt financings.

Howard joined Leerink Partners in 2021 from RBC Capital Markets, where he had worked since 2013, most recently as Managing Director covering Healthcare Distribution, Technology and related Services verticals. Prior to RBC Capital Markets, he held positions with Credit Suisse and Deloitte.

He holds a B.S. (with honors) from Lehigh University and an M.B.A. (with honors) from The University of Chicago, Booth School of Business.

Murphy Gallagher is a Senior Managing Director in Investment Banking at Leerink Partners.

Murphy focuses on the Biopharma sector and has over 17 years advising companies on capital markets, mergers and acquisitions and strategic advisory assignments. He is based in San Francisco and focuses on companies in western North America and the Asia Pacific region. He joined the firm in 2009 and prior to that was at Merrill Lynch, where he was a member of the Global Healthcare Investment Banking Group.

He earned a B.A. from Georgetown University.

Andrew Gitkin is a Senior Managing Director in Investment Banking at Leerink Partners.

Andrew joined the Firm in 2024 from Raymond James & Associates where he most recently served as a Senior Managing Director and Vice Chairman in the healthcare investment banking group. He brings over 25 years of healthcare-focused experience specializing in the biopharma and medical device sectors, including more than 100 transactions across M&A advisory, equity and equity linked financings. Prior to Raymond James, he served as a Managing Director and Head of West Coast Biotechnology at PiperJaffray & Company, and Senior Vice President at Moelis & Company. Andrew’s previous experience also includes roles as a Vice President of Tavistock Life Sciences and leading a biotechnology start-up. He started his career in the Equity Research Departments of SalomonSmithBarney and UBS.

He is a member of the UCLA Health System Board, and he earned his BBA from Emory University.

Tim Hotchandani is a Senior Managing Director of Healthcare Services & Technology Investment Banking.

Prior to joining Leerink Partners, Mr. Hotchandani served as a Managing Director at Rothschild & Co, specializing in the coverage of Life Science Technology companies globally. Previously, he was a Managing Director at Deutsche Bank and began his career as an investment banking analyst at Lehman Brothers and Thomas Weisel Partners LLC.

Mr. Hotchandani earned a Bachelor of Business and Economics from the University of Wisconsin-Madison. He is also a CFA® charterholder.

Robert Jackey is a Senior Managing Director in Investment Banking at Leerink Partners and is focused on coverage for Physician Services and Healthcare Provider companies. With over 18 years of Healthcare Investment Banking experience, he has led efforts to execute strategic transactions for a variety of public and private companies. Bob’s advisory and execution experience spans the spectrum of traditional provider organizations through high-growth healthcare disruptors, including domestic and multinational corporations.

Robert joined Leerink Partners in 2021 from Citigroup, where he spent over 16 years, most recently as Managing Director, covering the alternate site / sub-acute, behavioral, clinical staffing / outsourcing, dental, hospital / acute care, patient transportation, physician organization and veterinary verticals.

He holds a B.S. (summa cum laude) in electrical engineering as well as an M.B.A. from Fairleigh Dickinson University.

Dr. Anurag Jindal is a Senior Managing Director in Investment Banking at Leerink Partners covering the biopharma sector. He has over two decades of experience in the biopharma industry, as an investment banker, a consultant, and in strategic roles at a major pharmaceutical company.

Prior to joining Leerink Partners in 2021, Anurag was a Managing Director in the Healthcare Investment Banking group at Bank of America where he focused on strategic advisory and capital markets transactions for public and private companies in the biotech sector. Previously to his work at Bank of America, Anurag was the Deputy Head of Pharma M&A and in the Pharma Strategy Group at Novartis in Switzerland and in the Healthcare Investment Banking group at JP Morgan in both New York and San Francisco. He started his career as a Pharmaceutical Analyst at Health IQ in Los Angeles.

He holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley and a M.D. from the University of Southern California.

Aniket Kaloti is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2018, Aniket spent nearly 5 years in consulting, most recently at IQVIA, advising biopharma clients on a range of strategic projects spanning corporate finance, brand and commercial strategy, business development and M&A due diligence, and financial analysis. He has advised on a number of biopharma transactions at Leerink Partners including the sale of Decibel to Regeneron, the sale of Zogenix to UCB, and the sale of Dicerna to Novo Nordisk. Earlier in his career, Aniket advised multiple biotech and health-tech startups, including with respect to raising capital through government grants and private investors. Prior to joining the industry, he was a post-doctoral scholar in the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology.

He earned his M.B.B.S. (US M.D. Equivalent) from University of Mumbai, Masters’ in Biomedical Engineering at IIT Bombay and PhD in Neuroscience at Northwestern University.

Toby King is a Senior Managing Director in Investment Banking at Leerink Partners, focused on the Healthcare Provider continuum. With over 20 years of Healthcare Investment Banking experience, he has advised some of the industry’s leading healthcare providers and private equity firms across a wide variety of situations.

Toby joined Leerink Partners in 2021 from Citigroup, where he spent more than a decade, most recently as Managing Director and Head of North America Healthcare leading efforts with individual coverage across hospitals, alternate-site providers, behavioral health, outsourcing and post-acute care. Prior to Citigroup, he spent over ten years in the Healthcare Group at Merrill Lynch. Prior to investment banking, he worked at HCA’s Corporate Finance and Development group.

He holds a B.A. from Bellarmine University and an M.B.A. from The University of Chicago, Booth School of Business.

Michael Lindenberg is a Senior Managing Director within the Healthcare Services Investment Banking vertical of Leerink Partners.

Michael is primarily focused on physician services, multi-site healthcare and alternative site subsectors, as well as developing the Firm’s financial sponsor coverage efforts. With over 14 years of healthcare services-focused investment banking experience, Michael has advised a wide variety of financial sponsor and strategic clients on mergers and acquisitions, divestitures, restructurings, recapitalizations, buyouts, and capital raise transactions.

Michael joined the Firm in 2021 from the Guggenheim Securities Healthcare Services Investment Banking Group focusing on advising companies and financial sponsors across the healthcare services ecosystem. Prior to that, he was a Vice President in Jefferies Group’s Healthcare Investment Banking practice, having started his U.S. advisory career in the Life Sciences team of Deloitte’s Financial Advisory Services group in New York.

He received his MBA from the University of Rochester in New York, and his Bachelor’s degree from Stellenbosch University in South Africa.

Robert Minear is a Senior Managing Director of Investment Banking focused on leading the Firm’s financial sponsor origination efforts to further enhance the Firm’s growing private equity and leveraged finance businesses. With over 20 years of investment banking experience, Robert has advised a wide variety of domestic and international financial sponsor and strategic clients in connection with, inter alia, mergers and acquisitions, divestitures, spin-offs/split-offs, restructurings, recapitalizations, buyouts, takeover defense, proxy contests and capital raisings.

Robert joined the Firm in 2021 from Guggenheim Securities where he was a Senior Managing Director in the Healthcare Services Investment Banking Group focusing on advising companies and financial sponsors in the healthcare services sector. Prior to that, he was a Managing Director and Head of Healthcare Services Mergers and Acquisitions in Jefferies Group’s Healthcare Investment Banking practice and a member of the M&A groups at UBS, both in New York and London, and Deutsche Bank.

He received his Master’s degree in Aeronautical Engineering from Imperial College, University of London.

Sean Pitt is a Senior Managing Director in Investment Banking at Leerink Partners.

Sean has over a decade of healthcare investment banking experience and joined Leerink Partners in 2017. He has advised a broad range of biopharma companies across equity and strategic advisory assignments and transactions, having worked on over 200 transactions during his career.

He earned a B.S. from The University of Sydney, Australia.

Bernhard Sakmann, M.D., is a Senior Managing Director in Investment Banking at Leerink Partners covering the Medical Technology and Life Science Tools and Diagnostics sectors.

Prior to joining the Firm in 2024, Bernhard was most recently a Senior Managing Director at Evercore, providing strategic and financial advice to life science companies with a focus on medical technology and life science tools and diagnostics. Prior to joining Evercore in 2014, Bernhard spent over a decade in healthcare investment banking and in management consulting with Citigroup, Lehman Brothers and Oliver Wyman in New York and in London. Notable transactions for which Bernhard has been an adviser include Philips on its acquisitions of Biotelemetry and Capsule, GE on its acquisition of BK Medical and spin of GE Healthcare, Abbott on its acquisitions of St Jude Medical and Alere, Terumo on its acquisitions of Sequent Medical and Bolton Medical, Immucor on its sale to Werfen, Decipher on its sale to Veracyte, ArcherDx on its sale to Invitae,  Brooks Automation on its acquisitions of Genewiz and BioStorage Technologies, among many others.

He received a Doctorate in Medicine from Ludwig-Maximilians-University, Munich, Germany, a B.M. BCh. from Oxford University, UK, and a B.A. and an M.A. in Natural Sciences from Cambridge University, UK.

Jason Truman is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2024, Jason most recently was Senior Managing Director in the Biopharma Investment Banking Practice of Guggenheim Securities. Jason brings over 20 years of investment banking experience, where he advised a wide variety of domestic and international biopharma clients in connection with mergers and acquisitions, divestitures, spin-offs/split-offs, takeover defense, proxy contests and capital raising. Specifically, Jason has advised on strategic transactions that have involved leaders in the space including such companies as Gilead, Merck, Pfizer, Alexion, Arena Pharmaceuticals, NGM Bio, and Revolution Medicines. Prior to joining Guggenheim Securities, Jason specialized in mergers and acquisitions in the biopharma space working at firms including Credit Suisse and Morgan Stanley. 

He earned his MBA from the Darden School of Business at the University of Virginia and a BBA from the Ross School of Business at the University of Michigan.

Byron Webster is a Senior Managing Director in Investment Banking at Leerink Partners and is focused on the Specialty Pharmaceuticals sector. He has over 16 years of experience advising pharmaceutical companies on M&A, private and public financing assignments.

Prior to joining the Firm in 2015, Byron worked at Lazard where he was a Vice President in the Healthcare Group. Prior to Lazard, he began his career at Wells Fargo Securities.

He earned a B.A. summa cum laude from Wake Forest University.

Justin Reed is a Managing Director at Leerink Partners where he is focused on advising companies in the medical device sector on M&A and public and private equity offerings.

Prior to joining the Firm in 2024, Justin was most recently Managing Director at Evercore in the strategic advisory business. While at Evercore he advised on many transactions across the medical device sector including GE Healthcare’s spin from GE, GE’s acquisition of BK Medical, Lunit’s acquisition of Volpara, Philips’ acquisition of Biotelemetry and Capsule, SHINE Technologies acquisition of Phoenix, Abbott on the sale of Angio-Seal to Terumo and the sale of Epocal to Siemens Healthineers, and Terumo’s acquisition of Sequent medical. Justin was previously the founder of several medical device companies and holds multiple patents and academic publications for medical device technologies.

He earned his M.B.A. from Berkeley Haas School of Business, Master of Science in Physics from the University of Washington, and a Bachelor of Science in Physics from the University of Washington.

Dan Dubin, M.D., is the Vice Chairman, Co-President, Global Co-Head of Investment Banking at Leerink Partners and sits on the Firm’s executive committee.

For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients.  In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Tom Davidson is Vice Chairman, Co- President, and Global Co-Head of Investment Banking.  He serves on the Firm’s executive committee, where he shares responsibility for shaping the long-term strategy and driving the growth of Leerink Partners. Drawing on over three decades of experience advising CEOs and boards in the biopharma sector, Tom is focused on building a world class Mergers & Acquisitions business at Leerink Partners.

Over the last decade, Tom has been one of the most active M&A advisors in the biopharma sector globally. Notable recent deals include Amgen’s $27.3 billion acquisition of Horizon Therapeutics, the largest life sciences transaction of 2022, CSL’s $11.7 billion acquisition of Vifor, the largest life sciences transaction of 2021 and the $50 billion combination of Mylan and Upjohn which closed in 2020. In addition to his recurring work with some of the largest companies in the sector, he focuses a majority of his practice on working with emerging growth biotechnology companies, including Crown Laboratories, Novavax and Protagonist Therapeutics, each during 2024.

Tom joined the Firm in 2024 from PJT Partners where he was a founding partner of the firm. He previously served as Vice Chairman and Global Co-Head of Healthcare Investment Banking at Credit Suisse, where he was a member of the Global Investment Banking Operating Committee and as a Managing Director at Merrill Lynch.

Tom graduated from Yale University, summa cum laude and Phi Beta Kappa, with a BA in Economics and received his MBA from the Wharton School of the University of Pennsylvania.  Tom is a member of the Board of Trustees of the Rye Country Day School in Rye, NY.     

Caroline Cameron is the Chief Operating Officer of Investment Banking at Leerink Partners.

Prior to joining the Firm in 2024, Caroline was the Chief Operating Officer at Keefe, Bruyette & Woods (KBW, A Stifel Company). Prior to her time at Keefe, Bruyette & Woods, she worked in investment banking at Edgeview Partners (acquired by Piper Jaffrey), and as a research analyst at Fox-Pitt, Kelton and Macquarie Capital.

She earned a B.A. in Psychology and Economics from Hamilton College where she graduated Phi Beta Kappa.